Prescription Drug Overdose: Data-Driven Prevention Initiative (DDPI) | Apply Online

Frequently Asked Questions (FAQs)

What is the Prescription Drug Overdose: Data-Driven Prevention Initiative (DDPI)?

DDPI is a CDC cooperative agreement funding opportunity designed to strengthen and evaluate state-level efforts to prevent opioid overuse, misuse, abuse, and overdose. It focuses on helping states use improved data and more targeted prevention strategies to reduce harmful outcomes linked to prescription opioids, including emergency department visits and overdose deaths.

What is the overall goal of DDPI?

The overall aim is to help states use better data and more targeted prevention strategies to reduce measurable negative health outcomes associated with prescription opioids, such as opioid-related emergency department utilization and overdose deaths.

How is DDPI structured?

DDPI uses a two-tier framework. Applicants may pursue either (1) a foundational, capacity-building approach focused on planning and data, or (2) a more advanced approach that includes implementing comprehensive prevention activities (in addition to planning and data work).

What are the two tiers/components of DDPI?

The two tiers are:

• Planning and Data (base): Focused on strengthening core data and planning capabilities.
• Prevention in Action (enhanced): For states ready to implement a comprehensive prevention program; states pursuing this component may apply for both base and implementation funding.

What is the Planning and Data (base) component intended to support?

The base component is intended for states that need to improve core capabilities before running a broader prevention program. It emphasizes strengthening how the state collects, manages, analyzes, and applies opioid-related data, and engaging communities and partners to develop a practical strategy to scale up into a more comprehensive prevention program in the future.

What kinds of capacity improvements are emphasized under the base component?

Under the Planning and Data (base) option, states are expected to strengthen their ability to collect, manage, analyze, and apply data related to the opioid epidemic so they can understand overdose patterns, identify high-risk populations and geographic hotspots, and plan interventions that fit local conditions.

Does the base component include partner or community engagement?

Yes. In addition to improving data capabilities, the base component expects states to engage communities and partners and develop a practical strategy for scaling up to a larger prevention program.

What is the Prevention in Action (enhanced) component?

The enhanced component is intended for states ready to move beyond planning and put a comprehensive prevention program into operation. The expectation is more direct impact through implementation of prevention activities aimed at changing behaviors and conditions that drive prescription opioid dependence and abuse.

Can a state apply for both the base and enhanced components?

Yes. States pursuing the Prevention in Action (enhanced) component may apply for both the Planning and Data (base) work and the implementation funding.

What results does the CDC expect from the enhanced component?

The CDC frames desired results in terms of reducing measurable negative health consequences, including overdose deaths and opioid-related emergency department utilization. The enhanced component supports states that can translate data into interventions, monitor performance, and demonstrate progress.

What type of funding opportunity is DDPI?

DDPI is a discretionary grant offered as a cooperative agreement. This means CDC anticipates substantial involvement with awardees during the project, rather than a fully hands-off grant relationship.

Which federal agency sponsors this opportunity?

The sponsoring department is HHS, and the specific agency is the Centers for Disease Control and Prevention (CDC), through the National Center for Injury Prevention and Control (NCIPC).

Who is eligible to apply?

Eligibility is limited to state governments. This reflects the program's focus on statewide surveillance capacity, policy levers, and cross-jurisdiction coordination that states can provide.

What is the funding opportunity number?

The funding opportunity number is CDC RFA CE16-1606.

What is the CFDA number for this program?

The CFDA number associated with DDPI is 93.136.

What is the award ceiling?

The posted award ceiling is $750,000.

How many awards are expected?

The announcement indicates an expectation of 16 awards.

When was the opportunity posted?

The opportunity was posted on March 25, 2016.

What is the application deadline?

The original and current application closing date listed is May 27, 2016.

What makes DDPI "data-driven"?

DDPI emphasizes improving and using opioid-related data to understand overdose patterns, identify high-risk populations and geographic hotspots, and then plan or implement interventions that are targeted to local conditions and can be monitored for performance and impact.

Why does DDPI have a two-tier approach?

The program is built around the idea that states are at different stages in their response to the opioid crisis. The two-tier structure allows states to pursue either foundational capacity-building (Planning and Data) or a more advanced, action-oriented prevention approach (Prevention in Action), depending on readiness and infrastructure.

What outcomes does DDPI aim to reduce?

DDPI is intended to reduce harmful outcomes linked to prescription opioids, specifically including emergency department visits and overdose deaths.

What does CDC involvement look like under a cooperative agreement?

Because DDPI is a cooperative agreement, CDC anticipates substantial involvement with awardees during the project period, rather than operating as a purely hands-off funder.

Is this opportunity categorized under a specific sector or topic area?

Yes. The funding is categorized under Health, and it aligns with CDC NCIPC priorities, framing overdose prevention as part of injury prevention.